Levels of C-Reactive Protein and Glycated Albumin as a Risk Factor of Coronary Artery Disease in Patients with Type II Diabetes Mellitus

Tahir Hussain  Soomro; Rajkumar  Sachdewani; Zuhaib Zahoor  Soomro; Javed Khurshed  Shaikh; Asad Aslam  Korejo; Shagufta  Memon

doi:10.29054/apmc/2022.968

Tahir Hussain Soomro Assistant Professor, Department of Cardiology, Ghulam Muhammad Mahar Medical College, Sukkur Pakistan
Rajkumar Sachdewani Professor, Department of Cardiology, Ghulam Muhammad Mahar Medical College, Sukkur Pakistan
Zuhaib Zahoor Soomro Assistant Professor, Department of Cardiology, Ghulam Muhammad Mahar Medical College, Sukkur Pakistan
Javed Khurshed Shaikh Assistant Professor, Department of Cardiology, National Institute of Cardiovascular Diseases, Sukkur Pakistan
Asad Aslam Korejo Senior Registrar, Department of Cardiology, Liaquat University of Medical and Health Sciences, Jamshoro Pakistan
Shagufta Memon Associate Professor, Department of Physiology, Ghulam Muhammad Mahar Medical College, Sukkur Pakistan

DOI: https://doi.org/10.29054/apmc/2022.968

Keywords: Type-II diabetes mellitus, Coronary artery disease, Glycated albumin, Hs-CRP

Abstract

Background: It has been recognized that diabetes is a significant risk factor for coronary artery disease (CAD). Raised concentrations of the C-reactive protein (CRP) and Glycated albumin in individuals having type-2 diabetes mellitus and are related to the CAD occurrence and its severity. Objective: To determine the clinical benefits of hs-CRP and glycated albumin levels for CAD prediction in type II diabetic patients using a logistic regression model. Study Design: A cross-sectional study. Settings: Cardiology department of Ghulam Muhammad Mahar Medical College, in close collaboration with NICVD Sukkur Pakistan. Duration: For a one-year period from January 2019 to January 2020. Methods: The valuation of hs-CRP and the glycated albumin levels, were done in relation to the lumen narrowing levels among 102 patients who were scheduled for coronary angiography. Participants in the study were classified as normal if their lumen diameter was less than 30% (Group 1), mild CAD if it was 30-50% (Group II), moderate CAD if it was 51-70% (Group III), and severe CAD if it was more than 70% (Group IV). Data was entered and analyzed using SPSS version 26. Results: Using ANOVA, a relationship between glycated albumin, hs-CRP levels, and narrowing lumen diameter was found to be significant in all groups (p <0.01). The Tukey’s test after Honest Significant Difference (HSD) also showed a significant relationship between group III and group IV, except for hs CRP (p <0.01) (p 0.857). Conclusion: Both glycated albumin and hs-CRP tests can be used to assess CAD risk levels in patients with Type II diabetes mellitus and other associated risk factors.